Adverum Biotechnologies Stock Today
| ADVM Stock | USD 6.64 0.19 2.95% |
Performance1 of 100
| Odds Of DistressOver 81
|
Adverum Biotechnologies is selling at 6.64 as of the 29th of November 2024; that is 2.95 percent increase since the beginning of the trading day. The stock's lowest day price was 6.52. Adverum Biotechnologies has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Adverum Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of June 2023 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2014 | Category Healthcare | Classification Health Care |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 20.8 M outstanding shares of which 1.53 M shares are presently shorted by private and institutional investors with about 9.27 trading days to cover. More on Adverum Biotechnologies
Moving against Adverum Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Adverum Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Laurent Fischer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAdverum Biotechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adverum Biotechnologies' financial leverage. It provides some insight into what part of Adverum Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverum Biotechnologies (ADVM) is traded on NASDAQ Exchange in USA. It is located in 100 Cardinal Way, Redwood City, CA, United States, 94063 and employs 121 people. Adverum Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 134.18 M. Adverum Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 20.8 M outstanding shares of which 1.53 M shares are presently shorted by private and institutional investors with about 9.27 trading days to cover.
Adverum Biotechnologies currently holds about 235.84 M in cash with (90.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check Adverum Biotechnologies Probability Of Bankruptcy
Ownership AllocationAdverum Biotechnologies holds a total of 20.8 Million outstanding shares. The majority of Adverum Biotechnologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adverum Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adverum Biotechnologies. Please pay attention to any change in the institutional holdings of Adverum Biotechnologies as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Adverum Ownership Details
Adverum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 396.9 K | |
| State Street Corp | 2024-06-30 | 278.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 258.5 K | |
| Fmr Inc | 2024-09-30 | 234.7 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 206.7 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 204.6 K | |
| Bank Of America Corp | 2024-06-30 | 176.1 K | |
| Northern Trust Corp | 2024-09-30 | 155 K | |
| Soleus Capital Management, L.p. | 2024-06-30 | 147.2 K | |
| Bml Capital Management Llc | 2024-09-30 | 2.3 M | |
| Tcg Crossover Management, Llc | 2024-09-30 | 2 M |
Adverum Biotechnologies Historical Income Statement
Adverum Stock Against Markets
Adverum Biotechnologies Corporate Management
| Jim Wang | Chief Officer | Profile | |
| Andrew Ramelmeier | Chief Officer | Profile | |
| Romuald Corbau | Chief Officer | Profile | |
| Kalliopi MD | Senior Development | Profile | |
| Michael Steel | Senior Quality | Profile | |
| Rabia MD | Chief Officer | Profile |
Already Invested in Adverum Biotechnologies?
The danger of trading Adverum Biotechnologies is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adverum Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adverum Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adverum Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.